Gadeta B.V. is a Research & Development company established in 2015 which focusses on the development of innovative immunotherapies for cancer. The work of the company is based on the groundbreaking discoveries regarding the role of γδ T cell receptors (TCRs) in the broad recognition of both hematological and solid tumor cells and their potential use for the treatment of advanced malignancies as discovered by Prof. Dr. Jürgen Kuball, CSO Gadeta, at the University Medical Centre Utrecht (UMCU), The Netherlands.
